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REVIEW
Medicine and Biotechnology

Nanobiotechnology medical applications:
Overcoming challenges through innovation
Anthony Singer1,2,4, Eleni Markoutsa1,2,4, Alya Limayem1,4, Subhra Mohapatra3,4,5
and Shyam S. Mohapatra1,2,4,5*

Abstract

Biomedical Nanotechnology (BNT) has rapidly become a revolutionary force that is driving innovation in the medical field.
BNT is a subclass of nanotechnology (NT), and often operates in cohort with other subclasses, such as mechanical or electrical
NT for the development of diagnostic assays, therapeutic implants, nano-scale imaging systems, and medical machinery. BNT
is generating solutions to many conventional challenges through the development of enhanced therapeutic delivery systems,
diagnostic techniques, and theranostic therapies. Therapeutically, BNT has generated many novel nanocarriers (NCs) that each
express specifically designed physiochemical properties that optimize their desired pharmacokinetic profile. NCs are also being integrated into nanoscale platforms that further enhance their delivery by controlling and prolonging their release profile.
Nano-platforms are also proving to be highly efficient in tissue regeneration when combined with the appropriate growth factors. Regarding diagnostics, NCs are being designed to perform targeted delivery of luminescent tags and contrast agents that
enhance the NC -aided imaging capabilities and resulting diagnostic accuracy of the presence of diseased cells. This technology has also been advancing the ability for surgeons to practice true precision surgical techniques. Incorporating therapeutic
and diagnostic NC-components within a single NC can facilitate both functions, referred to as theranostics, which facilitates
real-time in vivo tracking and observation of drug release events via enhanced imaging. Additionally, stimuli-responsive theranostic NCs are quickly developing as vectors for tumor ablation therapies by providing a model that facilitates the location of
cancer cells for the application of an external stimulus. Overall, BNT is an interdisciplinary approach towards health care, and
has the potential to significantly improve the quality of life for humanity by significantly decreasing the treatment burden for
patients, and by providing non-invasive therapeutics that confer enhanced therapeutic efficiency and safety.
Keywords: Biomedical nanotechnology, nanotherapeutics, nanodiagnostics, theranostics, nanocarriers
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Introduction

Nanotechnology (NT) is a dynamic revolutionary force that is exponentially impacting
societies and environments globally. Through ground-breaking scientific and technological advancements, NT-based products have become integrated into the daily lives of nearly every human on the planet. The NT revolution truly embodies the interdisciplinary
approach and is bringing scientists together from nearly every area of the scientific study.
This world-wide collaboration is significantly enhancing the quality of construction materials, machinery, automobiles, electronics, renewable energy, transportation, common
appliances, consumer products, entertainment, agriculture, microscopy, scientific instrumentation, health care, diagnostic assays, and medicinal drug discovery (1-5) (Fig. 1).
NTs exemplify unique physiochemical properties that present novel functionality based
upon their extremely small size, large surface area, and quantum-mechanical dictation
(1, 3-5). Although the benefits are clear, there are growing concerns about the short and
long-term impact of the rapid NT expansion on the health and safety of humans and the
protection of the environment (1, 3, 4). To address these concerns, the NT community is working to generate regulations for nanofabrication, nano-synthesis and waste re-
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Figure 1. Nanoparticle and Nanomaterial Applications: Biomedical Research; Health Care; Environmental Protection; Energy Sources; Agriculture and Food; Consumer Goods; Construction, Smart Cite; and Electronics, Machines. (top left corner, then clockwise).

moval for the available nanoparticles (NPs) and nanomaterials
(NMs) (2, 3). These additions to the NT revolution will aid in
the development of products with the following properties:
non-toxic, biodegradable, biocompatible, scalable, smart or
programmable, eco-friendly, low energy consuming, and highly efficient (4, 5). Therefore, the future of NT has the potential to generate outstanding medical care, extremely powerful
computational power, stronger and more durable machinery,
eco-friendly cities, and an increase in the access to clean water
and food (3, 4)(6-8).
One of the most prominent subclasses of NT is Biomedical NT
(BNT), which focuses on the development of nano-based therapeutics, therapies, and diagnostic techniques that will advance
health care. Currently, only a few nanomedicines out of the thousands in research and development (R&D) are FDA approved,
but many BNT-based applications are being applied to the laboratory setting, such as diagnostic assays, imaging technologies,
biosensors, and in vitro tissue generation (9). These innovations
are enhancing the accuracy and precision of scientific research by
lowering the detection limits, enabling high-throughput screening (HTS) capabilities, developing bio-mimetic in vitro and in
vivo models, and allowing researchers to visualize and track their
nano-products within living organisms and environmental landscapes. Through the application of these models, lead selection and
optimization during the R&D of nanomedicine will be greatly enhanced, which will increase the therapeutic efficiency of the final
product. Overall, the current applications of BNT are significantly
enhancing scientific research, which is giving rise to precision and
personalized nano-based therapies and health care.
Personalized therapies are appearing to be the next major trend
The EuroBiotech Journal

in the BNT field, and will primarily focus on selecting the dose
type, level and strength based upon a patient’s specific disease profile. This advancement will heavily depend on the simultaneous
generation of comprehensive genomic, proteomic, metabolomics,
and cytomic databases that can be used to analyze results and select
the proper protocols for therapies. These omic-based studies will
facilitate accurate disease diagnosis and therapy selection that will
prove to be vital to the advancement of curative personalized medicine therapies for extremely high-mortality rate diseases, such as
cardiovascular and neurodegenerative diseases. Another example
can be seen in the development of personalized cancer therapies
that will be dictated by the cross-referencing of acquired patient
data with cancer-omic databases that contain information regarding the molecular or genetic carcinogenic agents, cell morphology,
surface and genomic biomarkers, protein expression, symptoms,
and alterations to metabolic pathways (10-12). By tailoring the design of nanoformulations to the omic-based information, they can
be created to express prolonged half-life, controlled drug release,
targeted delivery, stimuli-responsive behavior, and enhanced permeability across physiological barriers. Nanomedicine has quickly
surpassed the capabilities of conventional pharmaceuticals. In the
past, the majority of therapies were able to efficiently manage diseases, but typically did not offer the curative options that are now
becoming a possibility through the BNT advancement.

Nanotherapies: State of the art

Nanomedicines are designed to avoid inducing complications
that a patient would typically experience with conventional
pharmaceuticals, for example, toxicity induced from the administration of large, non-targeted dosages. However, nano147
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Figure 2. Biomedical Nanotechnology Applications: Nano-scale Imaging; Cancer Nanomedicine; Nano-Biomaterials; Tissue Regeneration; Biological 3D Printing; Bioinformatics; and Biological MEMS (top left corner, then clockwise).

medicines can typically be administered at much smaller doses
due to their innately high reactivity and functionalized drug
delivery. Nanomedicines are often loaded within or adhered
to functionalized NCs that confer enhanced therapeutic efficiency. The functionalization of NCs incorporates bioactive
molecules that facilitate control over the targeted delivery and
release of the payload, the selective and efficient permeation
across targeted physiological barriers, and the safe excretion and degradation within living organisms (13-16). These
nanomedicines are beginning to be generated to treat a wide
variety of health issues, including high mortality rate diseases
like cancer, cardiovascular disease, and neurodegenerative disease (Table 1). Some examples of highly effective nano-therapies currently in R&D or clinical trials include tumor ablation
through hyperthermia, phototherapy, or photo-chemotherapy;
cardiovascular therapies utilizing targeting nanomedicines directed to sites of thrombosis and atherosclerotic plaques; and
neurodegenerative therapies utilizing nanomedicines that can
permeate the blood-brain barrier (BBB) in order to inhibit the
progression, prevent the genesis, or possibly revert the symptoms of Parkinson’s and Alzheimer’s disease. As these BNT-enabled innovations continue to develop, many classically chronic diseases will begin to become curable.
Recently, many NCs are being functionalized with extracellular or intracellular stimuli-responsive behaviors that are
stimulated upon interaction with a selected biomolecule or cellular environment that causes a structural or conformational
change in the NC, thus inducing payload release or bioactivity

(17, 18). Common stimuli found in the cellular microenvironment of most disease sites includes detectable alterations from
endogenous pH, temperature, and glutathione levels (19). Extracellular stimuli can also be applied, which include induced
alternating magnetic fields, photothermal energy (NIR laser),
and photoacoustic waves (20). Induced changes in the NC can
range from alterations in porosity to the cleavage of molecular
linkers to activate a specific functionality. Techniques like these
have been shown to significantly enhance the therapeutic efficiency of in vivo administration by avoiding potentially toxic
non-specific interactions or premature drug release, while also
ensuring that an adequate concentration of drug is delivered to
the target site (18, 20-23).
Organic Nanocarriers
Novel NCs are constantly in demand, and through vigorous
BNT research, many have been discovered and are currently
under investigation for their potential to enhance the delivery
of conventional payloads or novel nanomedicines. A very common form of NCs are those made of natural polymers, which
includes proteins and lipids. Polymeric NCs are biocompatible, biodegradable, and non-toxic which makes them ideal for
medical application. Additionally, they can be highly functionalized in a manner that facilitates novel functionalities, and
control over the therapeutic delivery and release profiles. A
novel example can be seen in a recently developed star-shaped
poly (l-lysine) polypeptide (star-PLL) NC that has been shown
to facilitate enhanced gene therapy via highly efficient intra-
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Table 1. Novel Nanocarrier-based Drug Delivery Systems (Section 2.0)
Type

Material

Novel Physiochemical
Properties

Novel Therapeutic Applications

Ref

Organic Nanocarriers (Section 2.1)
- Stable internalization
facilitates intracellular release
of pDNA

- Stimulates tissue regeneration
- Utilizes lower doses of pDNA while maintaining
efficient expression levels

24

- pH-responsive release of
pro-drug at thrombosis

- Enhanced subsequent anti-thrombotic therapy

25

1

Polymeric

Star-PLL

2

Polymeric ***

PEG-chain
Micelle

3

Lipid Micelles

4

Sertoli Cells

Naturally derived cells

-Encapsulation of lipid micelles

-Enhanced immunoprotection and delivery to the
lung

30

5

Liposomes

Phospholipid
bilayer

- Formation of
immunoliposomes

- Cancer immunity therapies
- Delivery of nanoprimers

31

6

Nanobubbles ***

Phospholipid
bilayer

- Externally induced
ultrasonic-responsive behavior

- Enhanced tumor-permeability through induced
structural cavitation

34

cell-derived

- Biocompatible surface chemis- Laboratory stimulated biogenesis for their
try to originator cells, enhanced
utilization as biomimetic nanocarrier
targeting

35-38

Si-Ph, Si-N,
Si-OH

- Tunable porosity controls
loading & release

- Enhanced delivery of anti-malarial, & anti-leukemic
therapeutics

39,40

Au

- polyvinylpyrrolidone conjugates for enhanced internalization

- Non-toxic intracellular co-delivery of DOX & BLM to
41,42
lung cancer cells

Aluminum-based

- Functional and structural
tenability within lysosomal
low-pH environment

- Deliver antioxidant for up to one week while
lysosomally encapsulated

43

- Release anti-cancer agents upon interaction with
acidic pH or the tumor microenvironment

44

7

-Cationic Charge
Chitosan coated -Thiolation-enhanced
mucoadhesiveness

Exosomes

-Enhanced delivery of nucleic acids
-Enhanced retention and permeability within
mucosal membranes

26-29

Inorganic Nanocarriers (Section 2.2)
8

Mesoporous Silica

9

Gold Nanoparticles (AuNPs)

10

Metal Organic
Frameworks

11

ZIFs ***

- High degree of biocompatiZeolitic Imidazbility enhanced drug biodistriolate
bution

Nano-platforms (Section 2.3)
12

Ocular
Nanowafers

Polymeric

- Structure has drug embedded - Achieve prolonged gradual release of ocular drug,
throughout nanowafer, and
improves ocular bioavailability & therapeutic effislowly degrades via hydrolysis ciency

13

Dental Adhesive
Nano-resins

Nano-scale
polymer

- Biocompatible structure, and
enhanced adhesion

- Self-cleaning and self-healing restorative methods

3

14

Microneedle
Patches

Alginate-based

- MNs increase transdermal
permeability

- Glucose-responsive release of exendin-4 for prolonged, on-demand Type-2 Diabetes therapy

47

15

Polymeric
Hydrogels

Filomicelles &
block co-polymers (PEG-blPPS)

- Conformational change in
response to physiological or
photo-oxidation

- At target site, Immunomodulatory NC-drug complex self-assembles
-Sustained release for up to 1 month

48

16

Static Tissue Regeneration Scaffolds

porous, fibrous,
acellular, hydrogel, microsphere, polymer

- Facilitate the growth of tissue
cells for nearly any organ
- Permeable to cells, growth
factors, and biomolecules

- Artificially stimulated cell proliferation in organ or
artificial implant therapies

49,50

17

Dynamic Tissue
Regeneration
Scaffolds

Natural – PNIPAM polymer

- Thermo-responsive
conformational changes
- Heat > 32⁰C forms scaffold

- Heat <32⁰C shrinks scaffold and releases tissue
culture
- Future, grow implantable tissue cultures in vitro
with patients cells

51

18

Thermosensitive
Nanogels

PNIPAM

- Thermo-responsive
conformational changes

- Controlled drug release via NIR irradiation

20

45,46

*** = stimuli-responsive
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cellular plasmid delivery to mesenchymal stem cells (MSCs).
This delivery mechanism significantly enhanced the transgene
expression of bone morphogenetic protein-2 and vascular endothelial growth factor to stimulate MSC-mediated tissue regeneration (24). The star-PLLs are cationically charged, which
facilitates a simple self-assembly synthesis procedure that facilitates strong adhesion of plasmid DNA (24). This NC also
presents ideal properties to act as a framework for the gene
therapy of various target cells in future applications. Another
example of a self-assembled polymeric NC can be seen in a Diosgenin pro-drug anti-thrombosis agent where one molecule
of the pro-drug is bound to a single PEG chain via a cleavable
Schiff bass bond (25). When these monomeric units are placed
in solution they self-assemble into PEG micelles that confer
enhanced circulation time and controlled release of the prodrug in response to the acidic pH encountered upon arrival to
the thrombus site (25). This prodrug facilitates the prevention
of arterial and venous thrombus formation by increasing the
subsequent Diosgenin therapies bioavailability and attraction
to the desired endogenous targets (25).
Another vital group of polymeric NCs are those that are
functionalized or composed of the naturally-derived polysaccharide, chitosan. Chitosan possess many ideal properties that
make it therapeutically beneficial; it is biocompatible, biodegradable, mucoadhesive, antimicrobial, non-immunogenic,
neuroprotective, and non-toxic (26-28). Additionally, the cationic surface charge of chitosan has been exploited in developing gene therapies to generate strong electrostatic interactions
with gene silencing plasmids that facilitate stable delivery to
the target site (27). Pure chitosan NPs express poor transfection rates, but modifications, such as complexation with polymers or lipids, have been shown to increase this ability (27,
28). For example, a genetically-targeted microbicide has been
developed that is composed of lipids coated with a layer of chitosan that contains anti-HIV/SHIV siRNA-encoding plasmids
(26). Based on the advantageous properties of chitosan, this NP
was able to perform anti-HIV gene delivery to the intravaginal
mucosal membrane (26). Chitosan has also been thiolated to
further enhance the gene and drug delivering capabilities of the
NPs. Thiol groups decrease the cationic surface charge of chitosan but does not interfere with the complexation of nucleic
acids (28). In fact, this decrease in charge facilitates enhanced
mucoadhesiveness, sustained drug delivery, and improved epithelial permeability (27, 28). In one study, a thiolated chitosan
NC was utilized and shown to significantly enhance the anti-inflammatory effects of the anti-asthma drug, theophylline,
due to the increased and prolonged absorption into bronchial
epithelial cells (27). This NC presents an optimal vehicle for the
treatment of cases of chronic allergic inflammation (27).
Another prominent group of polymeric NCs are lipid micelles, which have been being utilized to safely deliver toxic
anti-cancer drugs to tumors. One example can be seen in the
encapsulation and delivery of paclitaxel via micelles composed
of a chitosan derivative, N-succinyl-chitosan, and lipoic acid
(29), In addition, these micelles were bound with low-density

lipoprotein complexed with siRNA targeting multi-drug resistant pathways in cancer cells (29). This NC presents acidic
-stimuli responsive behavior that induces drug release at the
tumor microenvironment (29). Based on the enhanced tumor
cell cytotoxicity, this NC presents a promising model for the
co-delivery of siRNA and anti-tumor drugs to eliminate multi-drug resistant cancer cells (29). Another example can be seen
in the treatment of lung cancer via DOX encapsulated in lipid
micelles (30). However, this NC is subsequently loaded within
Sertoli cells, which are biocompatible, naturally-derived cells
that facilitate immunoprotection during drug delivery (30).
Sertoli cells also avoid the physiological rejection of encapsulated NCs, and naturally translocate, become entrapped, and
lyse within precapillary vascular beds within the lung (30). The
Lysis facilitates the release of the lipid micelles and has been
shown to increase the anti-tumor effects of DOX due to the
enhanced and stable delivery (30).
Liposomal NCs are among the few that have been FDA approved for clinical application based upon their glorified amphiphilicity that facilitates non-toxic delivery of nearly any
anti-cancer drug, and for their biocompatibility that allows
them to be safely excreted and degraded within the body. Recently, a novel type of PEGylated liposomes was developed,
called immunoliposomes (ILs), that are revolutionizing
cancer immunotherapies. ILs can safely establish anti-cancer immunity by delivering cytokines and immune agonist
antibodies that often cause severe toxicity due to high systemic exposure (31). In response, PEGylated immunoliposomes (ILs) are being developed that can establish anti-cancer
immunity in a non-toxic manner. In one study, ILs had the
immune agonists IL-2 and anti-CD137 covalently adhered
to their surface and were functionalized to express significantly enhanced permeability and retention (EPR) in order
to permeate into the tumor microenvironment (31). The ILs
alter the cytokines’ pharmacokinetics and biodistribution in
a manner that successfully confers cancer immunity without
generating toxic-effects (31).
However, a major challenge to conventional systemic drug
delivery is the non-specific uptake of nanomedicines by the
reticuloendothelial system (RES), which inhibits payload
delivery and imparts toxicity within RES-associated organs,
such as the liver, spleen, and kidney (32). In response, there
has been a focus on developing nanoprimers that can prepare a
patient’s body for the subsequent administration of nanomedicines in a manner that will reduce the therapy’s risk profile (33).
In a recent study, it was demonstrated that the intravenous
administration of intralipids one hour prior to therapy was
shown to decrease RES uptake, while increasing the nanomedicine’s bioavailability (32). Intralipids interact with the
RES, which allows an increased amount of the nanomedicine
to arrive at the target site (32). This study found these synergistic effects to exist for anti-cancer therapies using Abraxane, Marqibo, Onivyde, and a novel platinum-containing
anti-cancer nanodrug. Advantageously, it is not required that
modifications be applied to the payload or its carrier in order
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to confer this synergism, which makes it translatable to other
BNT-based therapies (32). Another similar study utilized a
non-toxic liposomal nanoprimer that presented low levels of
hepatic accumulation and increased the subsequently administered nanomedicine’s systemic bioavailability (33). It was found
that by loading cytochrome inhibitor within the nanoprimer,
the efficiency of docetaxel treatment significantly increased
(33). In both cases, these lipid-based nanoprimers can be modified, through unique functional design, to express efficient
priming for a broad range of nano-based therapies (32, 33).
Another novel liposomal application has been developed
that utilizes liposome-nanobubble ultrasonic-responsive NCs
for the enhancement of anti-cancer drug delivery (34). The
LNs are comprised of phosphatidylserine and a paclitaxel
payload, which confers pro-apoptotic effects that advance
cancer cell death (34). In addition, the use of ultrasonic frequencies allows contrast-enhanced imaging of the location
and tracking of the LNs in vivo (34). This allows them to be
directly targeted with 12 MHz frequency standard B-mode
sonography to induce cavitation in the structure and enhance
tumor-permeability of the LN (34). This ultrasonic-induced
conformational change stimulates the on-demand release of
paclitaxel, and through repeated exposure to the stimulus it
was found that a controlled pulsated release was able to be
accomplished. The conformation change also enhances the
cellular internalization of the LN 10-fold, and the expression
of paclitaxel-induced anti-cancer efficacy in vitro and in vivo
(34).
Novel NCs are constantly in demand, and through vigorous
BNT research, many have been discovered and are currently
under investigation for their potential to enhance the delivery of conventional payloads or novel nanomedicines. A very
promising recently discovered group of NCs are exosomes,
which are endogenous cell-derived phospholipid vesicles ranging from 30-150nm in size that express biocompatible surface
chemistry to their originator cells (35). Due to their biomimetic membranes, they are being examined for their function as
enhanced targeted NCs that can deliver drugs across biological
membranes and are non-immunogenic due to their biocompatibility with cell membranes. Exosomes have high loading
capacities and can be greatly modified through surface conjugates to derive unique functionality, such as site-directed payload delivery and release (35). Another interesting function of
exosomes can be seen in their utilization in the development of
proteomic libraries by comprehensively analyzing the composition of exosomes that have budded from cancer cells (36, 37).
Exosomes express the same surface biomarkers and internal
molecular counterparts that are expressed on their originator
cell, which provides information regarding the intracellular
communication and signaling between cancer cells and potential therapeutic targets that can be utilized to enhance cancer
therapy (36, 37). This technique has successfully identified over
6,000 cancer-associated proteins, many bioactive-cancerous
agents, and various biomarkers that can be integrated into anti-cancer therapeutics (36).
The EuroBiotech Journal

Currently, techniques are being researched that can stimulate exosome biogenesis in a manner that produces consistently sized exosomes that can be utilized for reproducible and
precise drug development (35). Endogenously, the biogenesis
of exosomes is involved in cellular communication and chemical signaling (35, 38). The creation of reference databases that
focus on the contents, functions, locations, and stimulants of
these exosomes has stimulated research focused on enhancing
the rate of biogenesis and increasing their bioavailability within
diseased regions. For example, the stimulation of plasma-based
exosomes was induced to deliver miR-24 intracellularly, which
stimulates remote ischemic preconditioning that has the potential to attenuate reperfusion and myocardial ischemia-based
injuries that could lead to stroke (38). miR-24 is endogenously
produced and utilized in natural exosome communication and
was found to be at highest concentration within plasma-based
exosomes in rats (38). Induction of these exosomes enhances the delivery of miR-24, which reduces oxidative stress and
cardiomyocyte apoptotic levels by downregulating the pro-apoptotic protein Bim (38). Unfortunately, the true mechanism
of the induction of these exosomes is not well-established, but
through this study important anti-ischemic molecular targets
and endogenous anti-ischemic agents have been identified
(38). As the exosomal induction mechanism becomes known,
it will be able to be exploited, either genetically or though molecular induction, so that miR-24 can be more efficiently utilized for cardiovascular therapy (38).
Inorganic NCs
Currently, there are also large quantities of inorganic NCs in
R&D for their ability to enhance drug delivery systems. For
example, mesoporous silica 21 NCs are being developed for
their tunable pore size, high thermal conductance, avoidance
of toxicity due to biocompatibility and targeted delivery, and
high loading capacities (39, 40). In one study, MS NCs efficiently inhibited parasitic growth by safely delivering hydrophobic antimalarial drugs to targeted plasmodium infected
red blood cells (39). In another study, antibodies were covalently bound to MS NCs in order to confer targeting focused
on antigens specifically presented on the surface of leukemic
stem cells (40). Through antibody-antigen binding reactions
and proteomics studies, it was identified that IL-3 receptors
are actively internalized upon antibody binding, presenting
an optimal biomarker for highly effective targeted delivery of
anti-leukemic medicines (40).
Gold NPs (AuNPs) are a conventionally popular NC due
to their ideal physiochemical properties, but recent advancements in AuNP technology found that when they are bound
with biocompatible polymer conjugates they can facilitate enhanced therapy for malignant tumors (41, 42). AuNPs have
been shown to efficiently and safely deliver conventionally
“difficult-to-deliver,” hydrophobic and extremely toxic anti-cancer drugs, such as Doxorubicin (DOX) and bleomycin (BLM) (41, 42). The addition of polymers increases the
AuNPs’ stability, loading capacity, and cellular uptake (42).
151
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In a recent study focusing on DOX lung cancer therapy, it
was found that DOX’s ability to inhibit the growth of lung
cancer cells was significantly enhanced by loading it within
AuNPs that had polyvinylpyrrolidone polymers conjugated
to the surface (42). This non-toxic nanomedicine facilitated
highly efficient cellular internalization and intercellular release of DOX within lung cancer cells, which resulted in increased reactive oxygen species generation, sensitization of
the cells, mitochondrial membrane potential, and induction
of early and late apoptosis (42). In another recent study, it
was demonstrated that PEGylated AuNPs can successfully facilitate non-toxic intracellular co-delivery of DOX and
Bleomycin (BLM) to HeLa cells (41). The large difference in
the mechanistic action of DOX and BLM presents a model
that has the potential to decrease cancer drug resistance development while improving treatment efficiency (41). As this
delivery system advances it is projected that it will be able to
efficiently perform combination therapy focusing on ovarian
cancer (41).
Another developing group of inorganic NCs are metal organic frameworks (MOFs), which are porous nanostructures
that are constructed of metallic nanoparticles that are connected through organic linker molecules (43). MOFs express
functional and structural tenability along with a high degree
of porosity, which makes them applicable to drug delivery, catalysis, and sensing applications (43). In a recent study, aluminum-based MOF nanofactories were designed to protectively
cage anti-oxidative superoxide dismutase and catalase and be
delivered intracellularly to protect human cells from severe oxidative stress (43). These nanofactories were found to localize
within the cell’s lysosomes, but were still able to provide highly
efficient enzymatic delivery for up to a week based upon their
high chemical stability within low pH and significant protease
resistance (43).
Zeolitic imidazolate frameworks (ZIFs) are another MOF that
have recently been developed as a stimulus-responsive NC that
can undergo conformational changes in response to alterations
in environmental pH and interactions with biomimetic cell
membrane particles, such as liposomes (44). This allows ZIFs
to avoid premature drug release and nonspecific cellular interactions, and also confers the EPR effect when targeting cancer
cells (44). ZIFs express a high degree of biocompatibility and
structurally provide large, available pores that facilitate high
drug loading capabilities (44). ZIFs are being examined for
their efficiency in disease therapies associated with low pH environments, such as lysosomal and tumor microenvironments
(44). For example, ZIF pH-responsive delivery of curcumin
improved its bioavailability within tumors and its overall therapeutic effect (44).
Nano-Platforms for Medical Applications
During the last decades, advances in nano-engineered biomaterials such as hydrogels and nano-matrices have played a pivotal
role in the development of controlled drug delivery systems.
Drug release from these biomaterials is typically stimulated by

an external stimulus, such as an applied magnetic field or photothermal energy. A major focus of such nano-biomaterials is
the improvement of ocular drug delivery, because conventional
ocular administration techniques typically waste nearly 95%
of the drug (45, 46). Currently, an ocular nanowafer is being
developed which is synthesized of a polymeric hydrogel embedded with a drug that slowly dissolves causing the gradual
release of the drug (45, 46). Dentistry is another area that has
greatly advanced based upon NBT advancements. Nano-polymeric dental adhesive resins are now being used as self-cleaning and self-healing restorative methods (3). Microneedle
(MN) patches are another drug delivery platform shown to be a
painless and non-invasive alternative for transdermal administration (47). Recently, an alginate-based MN patch has been
developed that has the potential to provide a safe, long-term
and on-demand therapy for type 2 diabetes. The MN patch
is integrated with Ex4 and glucose oxidase, which facilitates
the glucose-responsive controlled release of exendin-4 (47).
A recent publication exemplified a filomicelle (FM)
self-assembling scaffold made up of block copolymers (PEGbl-PPS) that provides non-inflammatory bioresorption and a
high degree of customization (48). This allows it to be functionalized to perform sustained release of monodisperse
micellar NCs for up to one month when incorporated in a
hydrogel scaffold (48). This technology is being focused on
immunomodulatory treatments for cancer, cardiovascular
disease, and diabetes (48). The FM scaffold undergoes cylinder-to-sphere conformational changes when exposed to
photo-oxidation or physiological oxidation due to changes
in surface tension caused by the conversion of propylene
sulfide into more hydrophilic derivatives (48). The speed of
release can increase upon incorporation of photo-oxidizers,
such as ethyl eosin, within the FM (48). However, the true
novelty of this drug delivery mechanism stems from the retention and transport of non-loaded therapeutics, and the
self-assembling of the NC-therapeutic complex at the target
site (48). This was proven to be successful when analysis of
the resulting spherical micellar NCs found them to be loaded with molecular payloads that were internally added to the
FM scaffold (48).
In tissue regeneration, NT can be applied to reproduce or
repair damaged tissues. By using suitable NM-based scaffolds
and growth factors for artificially stimulated cell proliferation
in organ transplants or artificial implants therapy, nanotechnology can be useful and potentially lead to life extension.
Tissue regeneration is becoming a likely possibility as research
works towards the development of scaffolds that facilitate tissue
growth and are made from biocompatible NMs that are either
natural compounds, such as collagen or chitosan, or synthetic
compounds, such as PCL or PEG (49). There is a large variety of scaffolds currently in R&D that offer unique properties
such as oxygen or growth factor delivery, but universally they
all provide excellent tensile strength 49, 50. These factors facilitate the regeneration of a wide variety of tissues at various
locations throughout the body (49, 50). Currently, these scaf-
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folds can be placed on or within a wound to stimulate smallscale tissue regeneration, which is enhanced by the scaffolds
permeability to cells and biomolecules (49). In addition to
static scaffolds there are dynamic scaffolds in R&D that utilize
thermo-responsive shape changing polymers, called PNIPAM
(51). PNIPAM changes confirmation upon heating or cooling
beyond the transition temperature of 32⁰C (51). PNIPAM polymers expand when heated and can be placed in molds that
facilitate the formation of precisely scaled 3D tissue cultures
(51). Once in the mold, the permeable PNIPAM scaffold can be
inoculated with the desired tissue cells to produce the building
blocks for tissue regeneration (51). The tissue culture can be
released by reducing the temperature and can be utilized for in
vitro drug response profiling (51). As this technology progresses these building blocks will facilitate the complete growth of
tissue culture derived organs (51). Additionally, since the organ would be derived from the patient’s cells, it is expected that
there would be a lack of rejection complications during transplantation.
In addition, PNIPAM has begun to be studied for its application towards facilitating non-invasive stimuli-responsive
drug release. Currently, PNIPAM nanogels have been successful in controlling drug release in vitro, which is advantageous
regarding the implications towards assay development (20).
The thermosensitive responsiveness of PNIPAM facilitates the
generation of specifically drug release profiles through the administration of controlled irradiation via NIR light (20). These
nanogels were loaded with chitosan-modified chemically reduced graphene oxide vehicles that contained DOX (20). Upon
irradiation this platform was able to release a cytotoxic level of
DOX in a controlled manner, which shows promise for future
in vivo applications (20).

Nano-Theranostics (Table 2)

Nano-theranostics are nanoformulations that simultaneously
deliver a payload and an imaging agent, such as a contrast agent
or luminescent molecular tag, to a targeted location in order
to confer therapeutic benefit, track bioactivity during administration, decrease toxicity of conventional imaging agents, and
enhance the capabilities of nano-imaging instruments. By incorporating targeting moieties onto a theranostic nanoformulation, site directed imaging can be significantly enhanced, which
aids in disease detection capabilities. For example, a theranostic
nanoformulation is being developed that can target pancreatic
cancer cells for the delivery of gemcitabine, an anticancer drug,
and for labeling with gadolimium, a potent MRI contrast agent
(52, 53). The major advantage is that both of these compounds
are toxic in their free form and can cause many complications,
but in this case, toxicity is eliminated (52, 53). The gadolinimum
allows MRI tracking of the nanoformulation during systemic
circulation, ensuring delivery to the target location is successful
(52, 53).
However, manganese (Mn) has recently been replacing gadolinium as a less-toxic T1 MRI contrast agent. Mn also expresses
paramagnetic properties and an extended plasma half-life that
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greatly enhance the targeting capabilities for theranostic delivery
(54). For example, a PEGylated lipid micelle, DOPE, DC-Cholesterol, with a Mn-oxide core was developed for the co-delivery
of siRNA-encoding plasmid DNA and DOX for the treatment of
lung cancer (54). The formulation was administered intranasally
to mice and was found to provide an efficient vehicle for cancer
lung theranostics based upon the significant anti-cancer effect,
excellent T1 MRI contrast, and enhanced accumulation within
the lungs (54).
Another theranostic approach currently being developed targets the endothelial cells of inflammatory sites using novel biomimetic NCs called leukosomes (55). Leukosomes have properties similar to liposomes regarding their loading capacities,
ability to be functionalized, and biocompatible composition due
to their endogenous nature (55). In this study, the leukosomes
were targeted to endothelial biomarkers, VCAM-1 and ICAM1 (55). These markers also show promise as potential targets
for early diagnosis of atherosclerotic conditions (55). The leukosomes proved to be efficient vehicles for delivery of a broad
range of anti-inflammatory agents, as well as the co-delivery of
MRI contrast agents (55).
Chitosan has also been utilized to functionalize many NPs so
that they can perform theranostic functions that focus on delivering therapeutic plasmids and magnetic resonance imaging
(MRI) contrast agents that allow the researchers to treat and
visualize brains of individuals suffering from traumatic brain
injury or other neurodegenerative diseases. A recently developed chitosan NP has been developed that targets the brain and
incorporates manganese as a T1 MRI contrast agent (56). The
manganese is contained within a cross-linking agent, Mangafodipir, that forms a stable chitosan-plasmid DNA matrix (56).
Upon intranasal administration, this NP was found to efficiently
translocate to the brain and is hypothesized to be endosomally internalized by olfactory sensory neurons (56). The chitosan
matrix then becomes degraded by the endosomal environment,
which releases the plasmids intracellularly so that they can perform gene silencing (56). Another MRI contrast agent that has
been complexed with chitosan is superparamagnetic iron oxide
nanoparticles (SPIONs), which also facilitate magnetofection.
Magnetofection is the capability to attract NPs to a specific area
of the body through the application of an external magnetic
field (57). An example is SPION-containing block-polymer micelles coated with cationic polyethyleneimine (PEI) and chitosan
complexed with DNA (57, 58). These micelles were able to magnetically translocate to the brain, efficiently release the plasmid
DNA, and facilitate enhanced in vivo imaging (57, 58).
Additionally, chitosan has been complexed with graphene oxide to generate optimal non-toxic theranostic gene delivery vehicles that are showing promise for their applicability towards gene,
chemo- and phototherapies focused on the treatment of cancer
(59). The major advantage of these chitosan-graphene oxide NPs
is that they can facilitate the co-delivery of anti-cancer plasmid
DNA, DOX, and MRI contrast agents (59). This combinatory approach has generated a non-toxic and non-invasive platform for
cancer therapy and in vivo tumor imaging and diagnostics (59).
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AuNPs have also been utilized for theranostic therapies
targeted to inflammatory sites that correspond to atherosclerosis (60). AuNPs of various sizes and shapes are being utilized
for their ability to passively and actively target inflammatory
sites based upon affinity to specific inflammatory biomarkers,
such as accumulation of monocytes and macrophages in high
risk plaques (60). Upon arrival, the AuNPs act as a contrast
agent because they can become stimulated with photoacoustic (PA) waves emitted from a PA tomography laser (60). This
produces detectable pressure acoustic waves that are induced
by the thermoelastic expansion of the AuNPs (60). AuNPs also
showed the ability to target sites of thrombosis through biomarkers such as the cell surface glycoprotein receptor Integrin

αVβ3, which is expressed on activated endothelial cells and can
be utilized to visualize CVD-related angiogenesis (60). In this
study AuNPs were also presented for their capability, in cohort
with PA stimulation, to induce the opening of the blood brain
barrier in rats when exposed to focused-ultrasound (60). This
ability would allow researchers to better diagnose and study
the molecular environment of CVD-induced brain-related
symptoms, such as ischemic strokes (60). Overall, AuNPs are
showing great promise in regard to their ability to function as
a contrast agent, and also present theranostic potential due to
their large and flexible loading capacities that can be utilized
for the delivery of a broad range of nanomedicines (60).

Table 2. Novel Nano-Theranostics (Section 3.0)
Theranostic Nanocarriers (Section 3.0)
#

Type

Material

Novel Physiochemical Properties

Novel Theranostic Applications

- Bypass toxicity of potent anti-cancer - Efficient pancreatic cancer therapy
and MRI contrast agent
- Systemic MRI tracking

Ref

1

Liposomes

Phospholipid
bilayer

2

Lipid Micelle

DOPE, DC-Cholesterol

-Co-delivery of DNA, DOX, and manganese

-Enhanced accumulation in lungs,
Ideal for lung cancer theranostics

54

3

Leukosome

Biomimetic lipid
Bilayer

- Functionalized surface with atherosclerotic biomarkers for enhanced
targeted co-delivery

- Track delivery of anti-inflammatory
agents to atherosclerotic plaques
- Early diagnosis of conditions

55

4

Micelles

Block copolymers
w/ chitosan

- Biodegradable chitosan matrix
protects and controls release of its
payload

- Magnetofection driven gene therapy
- efficient bypassing of the BBB

5

AuNPs

Au

- AuNPs are PA contrast agents,
induction causes thermoelastic expansion

- Diagnose of cardiovascular related heart
and brain symptomatic profile
- Ultrasonic induced opening of BBB

52, 53

56-58

60

Novel Theranostic Tumor Ablation Therapies (Section 3.1)
#

Nano-Theranostic Formulation

Ablation Therapy & Stimulus

Anti-Cancer Activity

6

NCs w/ radiosensitive metal nanoenhancers

- Radiotherapy, stimulated via
gamma or X rays

- Oxidative stress, cell cycle arrest, or inhibit
DNA repair

7

NCs w/ magnetic superparamagnetic Iron Oxide NPs

- Hyperthermic, stimulated via
exposure to alternating magnetic
field

- High heat produced by quick alternation frequency of the magnetic NPs magnetic moments

62, 63

6

Photosensitive melanin loaded
PEGylated liposomes

- Photothermal, stimulated via
exposure to 808nm NIR light

- In vivo photoacoustic imaging & MRI guided
photothermal ablation of tumors in breast cancer patients

64

7

Lipid membrane coated Hollow
Silica-Carbon NPs loaded w/ photosensitizing agents

- Photodynamic, stimulated via
NIR exposure &subsequently via
interaction w/ ROS

- Increases (NAD+), decreases (ATP) available for
ATP-efflux pumps, blocks multi-drug resistant
properties in cancer cells for 5 days
- Creates window for treatment

66

8

Echogenic Folate-Targeted Polymersomes encapsulared with
air-bubbles, DOX, and Gemcitabine

- Redox-responsive, stimulated
via exposure to increase of GSH
concentrations within an environment

- Perform stable intracellular co-delivery of anti-cancer therapeutics into the cytosol of tumor
cells
- Facilitate ultrasound-enabled diagnostics

68

61

Surgical Applications of Theranostics (Section 3.2)
#

Nano-enable Surgical
Application

Nano-Theranostic
Formulation

9

In vivo Fluorescent Guided Therapy

10

NIR Fluorescence-Enhanced Diffuse
Optical Tomography – multimodal
- Tumor targeted NCs incorporatuse of real-time computed tomog- ing fluorescent NPs
raphy & MRI

- NCs w/ specific fluorescently
tagged cancer biomarkers

Advantage to Precision Surgery
- Every, and only, cancerous cell in a surgical
site is illuminated to ensure complete removal

69-71

- Real-time temporal and spatial 3D imaging for
the identification of biological & genetic causalities of disease
- Earlier detection & removal of tumors

72-73
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Theranostics for Tumor Ablation in Cancer Patients
Stimuli-responsive nanoparticles are being incorporated into
nanoformulations that are targeted for tumor cells, and upon
radiation, photonic, thermal, or magnetic stimulation they
can induce complete cancer cell ablation and enhanced tumor theranostics and avoid cytotoxic effects on healthy cells
that have conventionally been an issue regarding patient safety.
Radiotherapy, for instance, is a very effective mechanism for
the treatment of cancer but has typically been linked to severe
adverse effects due to the toxicity of the radiosensitizing agents
administered to the patient (61). However, safe and highly efficient radiotherapy can be accomplished in vivo through the
utilization of biocompatible tumor-targeted NCs incorporated with chemically inert radiosensitive metal-based nano-enhancers, such as gold, tungsten sulfide, iron, silica, and gadolinium (61). Once at the tumor sites they can be stimulated
through gamma-rays and X-rays, which results in cancer cell
death through the induction of oxidative stress, mitochondrial
failure, cell cycle arrest, or inhibition of DNA repair (61).
Magnetic NPs, such as superparamagnetic iron oxide, are another additive agent that has shown great promise towards the
advancement of non-invasive and safe cancer therapy through
targeted magnetically-stimulated ablation of tumor cells,
which is referred to as hyperthermia (62, 63). A recent study
found that hyperthermic efficiency was affected by the shape
of the iron oxide NPs, with square shapes generating more heat
energy and able to be synthesized at smaller sizes than spheres
(63). An extremely quick alternating external magnetic field is
applied to magnetic NPs that have arrived at the tumor site,
which causes their magnetic moments to alternate at a frequency that generates enough heat to ablate the cancer cells (62).
Magnetic NPs also confer theranostic capabilities because most
act as either T1 or T2 contrast agents for MRI (63). This ability
to image the NPs in vivo allows the tumor cells to be precisely
located and targeted in a manner that avoids inducing cytotoxic effects towards healthy cells (63).
Photo-sensitive nanoparticles that absorb NIR light and
convert it into heat are another optimal agent to incorporate
into anti-cancer medicines to accomplish complete tumor
ablation in response to destabilizing increases to the internal
temperature of the cells (64). This is referred to as photothermal therapy (PTT) and has been proven to exemplify superior,
non-invasive anti-cancer effects when compared to conventional surgical and chemotherapeutic techniques (64). Additionally, after PTT a patient experiences a short recovery period, significant decrease in the occurrence of toxic effects, and
low cancer recurrence rate (64). A recent study discovered that
endogenous melanin exemplifies optimal photothermal conversion efficiency to be utilized as a photo-sensitizing agent in
PTT targeted with an 808nm NIR laser for 10 minutes (64).
However, when administered alone, the PTT efficiency is not
significant (64). In response, melanin was loaded within PEGylated liposomes, which mitigated melanin’s potential toxicity and conferred theranostic capabilities of simultaneous
in vivo photoacoustic imaging and MRI guided photothermal
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ablation of tumors (64). It was found that when administered
in mice, complete tumor ablation was successful in mice infected with breast cancer (64). Based upon its bio-safe nature and
high photothermal efficiency, this theranostic nanomedicine
shows great promise for translation into clinical settings, and
as a framework for future PTT development for other types of
cancers.
Another application of photosensitizing agents can be seen
in a study where hollow silica NPs were loaded with photosensitizing agents and surface-functionalized for enhanced
retention due to charge stabilization within the acidic tumor
environment, which allowed them to be the active agent for
the induction of tumor ablation through non-invasive photodynamic therapy (PDT) (65). PDT is oxygen dependent, and
upon photonic stimulation this PDT agent has been shown
to induce the production of endogenous hydrogen peroxide,
ROS, which facilitates cellular internalization and causes mitochondrial failure (65). Interestingly, in another study ROS generation was stimulated to block multi-drug resistance in cancer
cells by altering the amount of ATP available for the overexpressed ATP-driven transmembrane efflux pumps (66). This
was accomplished through the administration of lipid membrane-coated silica-carbon (LSC) hybrid NPs that were targeted to the pyruvate molecule found in the mitochondria (66).
Upon NIR radiation, the generation of ROS begins, resulting in
a larger concentration of NAD+ through oxidation of NADH
(66). This example of PDT destroys the multi-drug resistance
for up to five days, which provides a therapeutic window for the
treatment of multi-drug resistant bacteria (66). This therapy
could generate a framework to address the growing challenge
and serious risk that is presented by the potential emergence of
multi-drug resistant cancer cells.
The final type of stimuli-responsive cancer therapy that is
currently rising to popularity is facilitated by redox-responsive
NCs. These NCs are responsive to the change in glutathione
(GSH) concentrations as they internalize into cells, which have
a much higher concentration in comparison to the extracellular environment (67). The gradient the NCs are exposed to in
terms of reduction potential is being harnessed as an endogenous stimulus that can trigger cytosolic intracellular release
(67). This mechanism has been especially applicable to cancer
therapies due to the presence of a GSH concentration in tumor
cells that is four times greater than that of healthy cells (67).
For example, echogenic polymersome vesicles are a novel theranostic redox-responsive drug delivery system composed of
extremely stable amphiphilic polymers, and encapsulated with
air bubbles that facilitate diagnostic ultrasound imaging (68).
These polymersomes were functionalized for folate-targeting,
and the co-delivery of gemcitabine and DOX (68). Currently
this model has only been tested within in vitro 3D spheroid
cultures, but was shown to express enhanced uptake and GSH
stimulated intracellular release within breast and pancreatic
cancer cells (68). However, this model has the potential to be
translated into an in vivo setting and confer potent anti-cancer
effects.
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Surgical Application of Theranostic Nanoparticles
A major focus of BNT diagnostics is the development of cancer imaging techniques to identify and locate cancer cells. For
example, an in vivo tumor imaging technology is being developed, called in vivo fluorescent guided therapy, which fluorescently illuminates every cancerous cell in the patient in order to
ensure complete and precise surgical removal (69). This technique even illuminates cancer cells that have not yet formed
into visible tumors, which reduces the risk of cancer recurrence after surgery (69). Cancer cells are targeted by specific
biomarkers that are fluorescently tagging by theranostic NCs.
The combination of diagnostic techniques and bioinformatics
allows the most unique, specific biomarkers for each type of
cancer to be identified for use as the target molecule, which ensures that only cancerous cells will be targeted. This technique
has been successful in mouse models and is on its way to becoming a common technique for the enhancement of precision
surgery (69-71).
Another unique diagnostic technology that has been developed utilizing multimodal in vivo imaging technology is called
Optical Tomography, which performs multimodal imaging utilizing μCT and MRI to produce 3D optical images (72, 73). NIR
fluorescence-enhanced diffuse optical tomography (fDOT) has
already been used to localize tumors in mice using fluorescent
nanoparticles. This technique utilizes engineered bioluminescence or fluorescent tagging to perform non-invasive in vivo
longitudinal and real-time imaging and temporal and spatial
defining of biological and genetic process associated with disease and drug delivery (72, 73). Such techniques will lead to
better understanding and diagnostic capabilities to detect diseases at earlier stages based upon identification of issues within
biological mechanisms and their specific causes (72, 73).
DNA-based Biomedical Nanotechnology Applications
(Table 3)
DNA technology, regarded as DNA origami (DNA-O), is currently rising to popularity due to its ability to perform a broad

variety of functions, including drug delivery, in response to the
flexibility of the design of the final structure. Additionally, synthesis and production of DNA-O components and structures
is fairly economical and easily achieved with DNA amplification techniques, such as PCR, and programmable self-assembly
through complementary sequence design (74). DNA technology has been greatly advanced by computational programs capable of facilitating precise design modeling that can be applied
to actual production of these non-conventional DNA-O structures (75). These programs convey a high degree of control over
the final structural characteristics, surface chemistry and functionality (74-76).
Primarily, DNA-O is being utilized to develop novel smart
drug delivery systems based upon its biocompatible nature,
amphiphilic structure, and ideal physiochemical properties
for drug loading, delivery, and release. (74, 76). For example,
DNA-O NCs are being examined for their enhancement towards the delivery of hydrophobic anti-cancer drugs, such as
DOX (74-76). Also, the structural customization of DNA-O
NCs allows them to express high affinity ligand-receptor interactions, and if desired, biomolecules can be incorporated that
confer stimuli-responsive behavior that can be designed for
nearly any stimulus (74-76). An example can be seen in the delivery of photosensitizing agents, such as gold nanorods, within
targeted DNA-O NCs that can facilitate photothermal ablation
of cancer cells (76). However, DNA-O NCs are not limited to
cancer; they can be nearly ubiquitously adapted to efficiently
treat any disease and deliver any drug. For instance, they are
currently being integrated into the CRISPR/Cas9 genomic editing system in order to provide stable and precisely targeted
delivery of the Cas9 proteins (76). Another unique advancement has been seen in the development of a DNA-O-based
scaffold that is designed to match the curve of cellular membranes (77).This scaffold is being examined for its potential to
repair damaged cellular membranes through binding and subsequent release of loaded biomolecules that facilitate cellular
repair and potentially cell membrane genesis (77).

Table 3. DNA-based Biomedical Nanotechnology Applications (Section 4.0)
DNA Origami – (DNA-O)
#

Type

Novel Physiochemical Properties

Novel Therapeutic Outcome

Ref

1

Targeted DNA-O NCs

- Stable & targeted intracellular delivery
of Cas9 proteins
- Delivery photosensitive gold nanorods
to tumor cells

2

DNA-O Scaffold

- Biomimetic curved-shape matches the
curve of a cell membrane

- Repair of damaged cell membranes by
delivering essential biomolecules

77

3

DNA Nanorulers

- Nanoscale DNA strands of exact size w/
fluorescent tags at equal intervals

- Enhance the accuracy of nanoscale
measurements in microscopy

78

DNA Integrated Live
Cell Circuits

- DNA-based “memory storage” system
that can accurately respond to extracellular signals through the production of a
DNA strand that will encode the required
response

- Diagnostic extracellular biomolecule
detection
- Stimulate existing cellular communications that induce specific cell states
- Future, rewire existing signaling pathways

75

4

- Enhanced CRISPR/Cas9 genomic editing
- Vehicle to facilitate photothermal ablation

74, 76
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DNA-O can also provide NCs that can facilitate the safe
delivery of contrast agents and fluorescent tags or markers to
target sites to enhance in vivo imaging capabilities (74-76). A
novel DNA-imaging agent is currently being developed, called
DNA nanorulers, which provides a tool that can be delivered to
sites destined for analysis by fluorescent microscopic imaging
(78). These nanorulers are precisely synthesized to be an exact size, and also incorporate fluorescent tags at equal intervals
along the DNA strand in a manner that simulates the ticks of a
ruler (78). DNA nanorulers present the potential to significantly enhance the accuracy of nanoscale measurements of imaged
biomolecules through superresolution (78).
Lastly, DNA-O exemplifies properties that make it advantageous for application towards the development of DNA/live
cell complexes that simulate electronic circuitry. These are
called integrated live-cell circuits, and they can develop appropriate responses to molecular or stimulus-based inputs (75).
The input stimulates the circuit to access incorporated DNA-O
memory storage structures that release the appropriate DNA
strand that encodes the desired output (75). The released signals stimulate the cell’s endogenous biosynthetic machinery to
produce the desired DNA sequence that becomes either building blocks to repair the circuit or templates to produce outputs
and cellular signals in the form of proteins or genetically encoded fluorescent reporters (75). These circuits can be used
in diagnostic studies to analyze extracellular biomolecule
presence, but can also be prospectively utilized to trigger intracellular cellular signaling pathways in a stimuli responsive
and controlled manner (75). Eventually, the goal is to be able
to implant precisely programmed DNA circuits into in vivo
biological systems in order to stimulate existing cellular communications that induce specific cell states, such as apoptotic
states to fight against detected disease inputs (75). Additionally, researchers are examining ways that these circuits can be
programed in a manner that rewires existing signaling pathways to induce novel or enhanced functionalities (75).

Nano-enabled Diagnostics

BNT-enabled diagnostics has incorporated mechanical and
electrical NTs to create bioanalytical devices called Biological
Micro-Electro-Mechanical Systems (BioMEMS). Initially BioMEMS application was primarily in vitro to characterize physiochemical properties of nanoparticles such as size, mass, and
zeta potential; detection of specific biomarkers for disease diagnostics; or identification of contaminants or pathogens in biological samples such as body fluids, or water samples (79, 80).
A major advantage of BioMEMS is their ability to perform HTS
at an extremely fast rate for many samples (79, 80). However,
the miniaturization and advancements towards micro-cantilever technology has further increased the accuracy, sensitivity
and detection capabilities of BioMEMS while decreasing the
cost, the amount of solvent and sample used per assay, and the
speed of result acquisition (79, 80).The continued trend of miniaturization has led to the generation of cell-on-a-chip technologies that have the capability to perform analysis on the level of
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single cells (81). Also, organ-on-a-chip technologies have been
generated that simulate 3D tissue environments that represent
in vivo cell-cell interfaces and can accurately depict biochemical, genetic, and metabolic activities in real time (80, 81). These
biosensor-based chip technologies have made it possible to
detect diseases in their earliest stages due to their extremely
small detection limits and their ability to detect the presence of
disease cell-by-cell (80, 81). These technologies will revolutionize in vitro assays and allow simple, non-invasive, inexpensive
devices for patient-performed in-home diagnostics. A limiting
factor off the chip technologies is that they only allow extracellular and surface-cellular detection, but another biosensing
technology called nanoscale endoscopes allows subcellular
detection of organelles and cytoplasmic biomarkers (82). The
endoscope non-invasively probes a cell and photonically stimulates fluorescently tagged organelles to detect diseased cells
based on individual intracellular signals (82). This technique
provides insight into intracellular disease profiles, which will
significantly aid in the development of future therapies.
Recently, molecular electrodes have been developed for diagnostic purposes. A promising model for the electrochemical detection of mutated DNA sequences and single-nucleotide polymorphisms utilizes graphene electrodes that are
functionalized with chitosan (83). Graphene’s physiochemical
properties make it an excellent material for the generation of
biosensors due to its exceptional electronic, mechanical, and
thermal properties (83). The chitosan facilitates the covalent
attachment and immobilization of a single stranded DNA sequence that is complementary to the target sequence (83). The
electrode platform is added to the biosensing device, which is
then subjected to voltammetry (83). During the assay completely, complementary DNA sequences bind the DNA of the
electrodes. This determines if the target sequence is present in
the biological sample (83). This rapid and inexpensive platform
presents the potential to be utilized as a point-of-care diagnostic device that can detect disease-related DNA mutations in a
sample taken from a patient (83). As this technology continues
to progress multiplexed electrodes can be generated that will
be able to characterize the genetic profile of an individual in
comparison to a specific disease (83).
There are also many types of bioassays that are being developed that provide in vitro models that closely represent in vivo
microenvironments and enhance the precision and accuracy of
drug response profiling. For example, polymeric electrospun
fiber-inspired smart scaffolds (FiSS) are being utilized during
in vitro cancer studies to facilitate the formation of 3D tumoroids (84). The tumoroids are formed from extracted tumor
cells of a specific cell line that were grown in mice (84). Advantageously, tumoroids exemplify reduced sensitivity towards
anticancer drugs, which improves the quality of screenings for
anticancer compounds in comparison to the classical models
(84). Additionally, this technology can be utilized to culture tumor cells from patient biopsies to perform accurate diagnostics
that can aid in the development of personalized cancer therapies (84). Another example can be seen in in vitro microfluidic
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blood brain barrier (BBB) models that accurately represent in
vivo conditions (85). Additionally, single cell additive manufacturing is assisting in the generation of 3D bioprinted in vitro tissue and organ models that can be utilized in regenerative
research (86).
Additionally, lipid technologies have begun to revolutionize
high throughput in vitro assays by decreasing the size of each
compartment (or well) on microarrays using evaporative edge
lithography to stamp lipid bilayers in a specific orientation,
producing microarrays with the potential to test 50,000 drug
candidates in a single assay (87). This lipid technology was also
used to develop lipid-oil droplet arrays that do not require additional solvent and can assay lipophilic drugs (87). These assays can also determine the dose-dependent bioactivity of large
quantities of small molecules to determine their potential as a
nanotherapeutic in nanomedicine (88, 89). This lipid technology has also been used in the development of “nanointaglio,”
which detects analytes in air vapors by optically sensing topographical changes to lipid grates upon the passage and binding
of vapor analytes (88-90). Overall, bioMEMS are completely
revolutionizing in vitro analyte and disease diagnostics, biological sample analysis, NP characterization, and lead selection
through bioactivity high throughput screenings.
Another truly innovative technology is the development of
nano-based implants to repair damaged or inactive sensory organs, such as an artificial ear that can allow a deaf person to
hear or an artificial nose that can grant someone the sense of
smell (90, 91). These implants are essentially BioMEMS that are
specifically functionalized to detect sensory stimuli and use the
electronic aspects to send signals to the desired cells, typically
central nervous system cells (90, 91). For example, a cochlear
ear implant is being developed that utilizes nanoelectrodes to
plasmonically stimulate neural and cardiac cells to confer the
ability to hear for the hearing-impaired (91). Nano-implantable
technologies, such as gradually dissolving hydrogels, are also in
development for implantable diagnostic devices and implantable drug administration devices that can allow point-of-care,
in-home treatment and controlled drug release without issues
of patient non-compliance. The future goals of BNT include
innovative technologies with the potential to facilitate drastic
changes in what was once believed to be irreversible damage
and permanent health conditions of the human body, such as
amputation or inert deafness. These goals are being accomplished through the combination of functionalized BioMEMS,
“smart” biomaterials, and 3D bioprinting technologies.

Future Prospects of Biomedical Nanotechnology

In conclusion, the BNT revolution is proving to be a continually growing dynamic force that is generating innovations that
are altering the world’s perspective on medical care. Specifically, there will be a rise in the production and widespread utilization of highly therapeutic efficient personalized and precision
nanomedicines and nanotherapies. This integration will facilitate the elimination of the fear of mortality from conventionally chronic or fatal diseases and is also projected to discover

therapies that will extend the average lifespan. In cases where
tumors or harmful growths develop precision and assisted surgical techniques are greatly advancing to the point where they
can surgically remove single cells. Also, to repair surgical sites
or any form of tissue damage, BNT is facilitating the generation of many platforms for tissue regeneration that utilize an
individual’s cells, which will lead to the elimination of tissue
implant rejection. In the future the treatment burden to a patient will be significantly decreased based upon the development of prolonged and stable delivery systems that will lower
the number of administrative events. Additionally, many nanomedicines will be formulated into non-invasive, self-administrable, and high-patient-compliant administrative forms that
will further increase the ability for the patient to perform inhome therapy. Diagnostic devices, such as BioMEMS, will also
continue to become more cost-effective and easily functional
so that patients can perform in-home point-of-care diagnostics, which will also aid in the earlier detection of disease. As
these BioMEMS integrate with computer technology they will
be able to perform real-time communications with health care
facilities upon identification of disease and serious compliance
or toxicity issues. BioMEMS will also present products that will
be able to function as in vivo implants acting as functional or
sensory organs. Regarding scientific development, microscopy
and characterization instrumentation will continue to increase
in functionality, precision, and accuracy which will lead to particle level detection and differentiation. Overall, if implemented in accordance with appropriate regulation and safety-monitoring, BNT has the potential to enhance the worldwide quality
of life for humans across every continent.
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